Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603676'
s EV-to-FCF Range Over the Past 10 Years
Min: -593.57 Med: 24.76 Max: 1678.02
Current: 19.59
During the past 13 years, the highest EV-to-FCF of Xizang Weixinkang Pharmaceutical Co was 1678.02. The lowest was -593.57. And the median was 24.76.
SHSE:603676's EV-to-FCF is ranked better than 52.36% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.7
vs SHSE:603676: 19.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Xizang Weixinkang Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
Xizang Weixinkang Pharmaceutical Co's share price for today is ¥8.78.
Xizang Weixinkang Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.500.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Xizang Weixinkang Pharmaceutical Co EV-to-FCF Related Terms
Xizang Weixinkang Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co EV-to-FCF Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Xizang Weixinkang Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xizang Weixinkang Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Xizang Weixinkang Pharmaceutical Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Xizang Weixinkang Pharmaceutical Co's EV-to-FCF falls into.
Xizang Weixinkang Pharmaceutical Co's current Enterprise Value is ¥2,693 Mil.
Xizang Weixinkang Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥137 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xizang Weixinkang Pharmaceutical Co (SHSE:603676) has a EV-to-FCF of 19.59 as of Jul. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. This is 21% below median its historical median of 24.76. According to the industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #272 out of 571 companies in the Drug Manufacturers industry, placing it in the top 47.6%.
Is Xizang Weixinkang Pharmaceutical Co's EV-to-FCF too high?
Xizang Weixinkang Pharmaceutical Co's current EV-to-FCF of 19.59 is 21% below median its 10-year median of 24.76. The Drug Manufacturers industry median EV-to-FCF is 20.70. Xizang Weixinkang Pharmaceutical Co's value of 19.59 is 5.4% below this industry median. Based on the distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #272 out of 571 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Xizang Weixinkang Pharmaceutical Co has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Xizang Weixinkang Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Xizang Weixinkang Pharmaceutical Co ranks #272 out of 571 companies for EV-to-FCF. This puts Xizang Weixinkang Pharmaceutical Co in the upper half of its industry. The industry median EV-to-FCF is 20.70. Xizang Weixinkang Pharmaceutical Co's value of 19.59 is 5.4% below this benchmark. While the company's 10-year median is 24.76 vs. the industry median of 20.70, Xizang Weixinkang Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.70, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xizang Weixinkang Pharmaceutical Co's current EV-to-FCF of 19.59 is 5.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Xizang Weixinkang Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xizang Weixinkang Pharmaceutical Co's current EV-to-FCF is 19.59, which is 21% below median its own 10-year median of 24.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xizang Weixinkang Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co (SHSE:603676) is currently considered Fairly Valued. The stock's GF Value™ is ¥8.93, compared to a current price of ¥8.78 — trading 1.7% below its estimated fair value. The current EV-to-FCF is 19.59, which is 21% below median its 10-year median of 24.76 and 5.4% below the Drug Manufacturers industry median of 20.70. Xizang Weixinkang Pharmaceutical Co's overall GF Score™ is 74/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Xizang Weixinkang Pharmaceutical Co (SHSE:603676), the current EV-to-FCF is 19.59 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xizang Weixinkang Pharmaceutical Co (SHSE:603676) Overvalued in 2026?
Based on GuruFocus' analysis, Xizang Weixinkang Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.78 is trading 1.7% below its estimated GF Value™ of ¥8.93.
GuruFocus considers Xizang Weixinkang Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:603676:
EV-to-FCF: 19.59 (21% below median its 10-year median of 24.76)
GF Value™: ¥8.93 vs. price of ¥8.78 (1.7% below fair value)
Industry Position: 5.4% below the Drug Manufacturers median (#272 of 571)
No single metric tells the full story. See the SHSE:603676 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xizang Weixinkang Pharmaceutical Co Business Description
AddressYuanqu South Road, 3rd Floor, Building 4, Industrial Center, No. 5, Zone B, Lhasa Economic and Technological, Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Xizang Weixinkang Pharmaceutical Co Ltd is engaged in research & development, production and sales of chemical pharmaceutical preparations and their raw materials. It also produces and sells liver protection drugs and antibiotic products.
74GF Score
Get the complete analysis for SHSE:603676
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603676 has been successfully added to your 
